Material and Method: We re-evaluated 80 cases of thyroid neoplasms, comprising 40 cases of follicular variant of papillary thyroid carcinoma and 40 cases of follicular neoplasm, diagnosed at Dicle University Medical School, Department of Pathology between 2005 and 2008. All neoplasms were stained with CD 56, HBME-1 and p 63 compared to each other. Statistical analysis was with Student's t test and the Yates corrected chi-square test.
Result: There was no statistically significant difference in the expression of CD 56 between follicular neoplasms and papillary carcinomas, but HBME-1 and p63 expressions were statistically significantly different between these neoplasms (p=0.005, p=0.0001).
Conclusion: The use of HBME-1 and p63 may be helpful in differentiating papillary carcinoma, particularly follicular variant, from follicular neoplasms.
Thirteen PTC subtypes have been defined. The most common subtype is the follicular variant. Distant metastases such as to the lung and bones in addition to multicentricity vascular invasion and nodal distribution are frequently encountered in follicular variant PTC [1],[3].
Various immunohistochemical markers have been used in the differentiation of PTC and especially the follicular variant from other follicular tumors [4]-[7]. We studied the CD56, p63, HBME-1 immuhohistochemical markers to determine their contribution to the differential diagnosis of PTC follicular variant with follicular tumors.
CD56 is a neural cell adhesion molecule and its migration influences the migratory characteristics of tumor cells.
CD56 is present in the follicular epithelial cells of the normal thyroid [8]. Various studies have reported that CD56 does not stain in PTC while staining is present in most follicular tumors [4],[5],[9].
The HBME-1 (Hector Battifora Mesothelial cell) antibody has been shown in mesothelial cells by Battifora et al.. HBME-1 is the most specific (96%) marker known for malignant tumors derived from follicular epithelium [10]-[12]. It is used in the differential diagnosis of PTC and papillary hyperplasia and has been shown to be quite specific [5].
p63, a member of the tumor suppressor gene family, is the homologous nuclear transcription factor of p53 and is essential for normal development [13]-[16]. p63 plays a key role in epithelial proliferation and differentiation and causes defects in epithelial differentiation [16]. Various studies have demonstrated that p63 is present in the basal layer of squamous epithelium, in breast and prostate myoepithelial cells and in the transitional epithelium of the bladder [16]-[18]. Its tumor suppressor effects are quite controversial although it is from the p63 tumor suppressor gene family and mutations in these genes are quite rare in human malignancies. Focal staining is expected in PTC while some reports state no staining in other thyroid tumors [4],[19],[20].
Immunohistochemical Method:
The sections that were 4 μm thick and obtained on
positive charged slides from the paraffin block for the
immunohistochemical study with CD56/NCAM-1
HBME-1 (Mesothelin), and p63 (Thermo Scientific, USA)
antibodies were deparaffinized. Dehydration was performed
in 96-degree ethyl alcohol and antigen recovery was carried
out in a microwave oven in pH 6.0 citrate buffer solution.
The sections were cooled to 20 minutes at room temperature
and kept in 10 minutes 0.3% hydrogen peroxide solution.
PBS (phosphate buffer saline, PH 7.4) was used to wash the
sections while the standard avidin-biotin complex (ABC)
method was used as the immunohistochemical method.
AEC (3-amino-9-ethylcarbazole) (Ultra Vision LP Value
Detection System HRP Polymer&AEC Chromogen, Thermo
Scientific, USA) was kept in the substrate solution for 10
minutes and washed with distilled water. Counterstaining
was performed for 2 minutes with Mayer hematoxylin.
The preparations were evaluated with an Olympus model
CX21FS1 light microscope.
The positive controls used were pancreas for CD56, pleura for HBME-1, and skin tissue for p63.
Evaluation:
Cytoplasmic and membranous staining for CD56
basolateral membranous staining for HBME-1 and nuclear
and cytoplasmic staining for p63 were accepted as positive
in the tumor cells. For the three antibodies, >10% staining
in the tumor was accepted as positive while a value <10%
was negative.
Student’s t test and Yates corrected Chi-Square test were used for statistical analysis.
HBME-1 staining was present in 5 (12.5%) and absent in 35 (87.5%) follicular tumors. There was diffuse staining in 16 (40%) PTC cases (Figure 2) and no staining in 24 (60.0%). There was a statistically significant difference between follicular tumors and PTC for HBME-1 staining (p=0.005).
p63 staining was present in 3 (7.5%) follicular tumors (2 follicular adenomas, 1 follicular carcinoma) and absent in 37 (92.5%). Staining was present in 12 (30.5%) PTC cases (Figure 3) and absent in 28 (70%). There was a statistically significant difference between follicular tumors and PTC for p63 expression (p=0/0001). PTC cases were found to show a higher rate of staining with p63 than follicular tumors.
Figure 1: CD56 staining in papillary carcinoma (x400).
Figure 2: HBME-1 staining in papillary carcinoma (x400).
Figure 3: Nuclear and cytoplasmic p63 staining in papillary carcinoma (x200).
CD56 has been reported to be an antigen related to the differentiation of follicular epithelium [23]. Normal thyroid tissue, benign thyroid disease and follicular tumors show membranous staining while staining in PTC is weak or absent [4],[24]. CD56 has also been reported to decrease tumor invasion by suppressing VEGF-D [25] .
We found no CD56 staining in 35% of both follicular tumors and papillary carcinomas. There was no statistically significant difference between follicular tumors and PTC regarding CD56 staining. Our results are not consistent with literature data. This may be due to our small number of cases or tumor differentiation.
HBME-1 is reported to be a reliable marker in the diagnosis of PTC and the differentiation of PTC and papillary hyperplasia [5] with a specificity of 96% in PTC [26] while a rate of 100% has been given for HBME-1/CK19 coexpression [27]. However, others report that HBME- 1 also shows immunoreactivity in follicular lesions such as follicular carcinomas, follicular adenomas, oncocytic tumors and hyperplasia [11],[18].
When compared for HBME-1 staining, we found focal staining in 12.5% of follicular tumors and diffuse staining in 40% of PTC cases in our study. There was a statistically significant difference between follicular tumors and PTC-1 for HBME-1 staining (p=0.005). HBME-1 was seen to show basolateral membranous staining in PTC, consistent with literature data, while the staining in the follicular tumor group was negative and accepted as negative [6],[10],[11]. No statistical study was performed as the staining feature was deemed to be inappropriate for statistical analysis. Various studies have reported no p63 staining or rare weak staining in normal thyroid tissue and non-PTC lesions while PTC cases frequently show areas of focal staining with high specificity [4],[28]. Although most other studies report nuclear staining with p63 [4],[13],[16], a study with meningiomas has reported nuclear and cytoplasmic staining in grade II and grade III meningiomas [29].
We found focal nuclear and cytoplasmic p63 staining in 7.5% of follicular tumors and 37.5% of PTC cases. Focal p63 staining was present in 82% of classic PTC and 50% of follicular variant cases with a general figure of 70% for PTC while follicular tumors showed weak staining at a rate of 20% (28). Our staining rate in PTC is lower than that in the literature but we found a statistically significant difference between follicular tumors and PTC cases for p63 expressions (p=0.0001). Taking our results and literature data into account, we feel that P63 may be an additional marker for PTC.
We believe that CD56 is not a reliable marker in the differentiation of PTC and follicular tumors but more extensive studies are needed on the subject. A detailed investigation of as many samples and sections as possible is suggested in cases with a histological suspicion of malignancy where the diagnosis is reached only by immunohistochemical tests [30]. However, we think that HBME-1 is not adequate in differentiating follicular variant PTC from other follicular tumors by itself and that p63 may be added to the commonly-used HBME-1, CK19 and galectin panel.
ACKNOWLEDGEMENT
This study has been supported by the Dicle University
Research Commission.
1) DeLellis R A, Williams ED: Tumors of the thyroid and parathyroid. In DeLellis RA, Lloyd RV, Heitz PU, Eng C (Eds): WHO classification of tumours. Pathology & Genetics Tumors of Endocrine Organs. Lyon, IARC, 2004, 49-133
2) Maitra A: The Endocrine System. In Kumar V, Abbas AK, Fausto N, Aster JC (Eds): Robbins and Cotran Pathologic Basis of Disease. 8th ed., China, Elsevier Saunders, 2009, 1107-1130
3) Li Volsi VA, Albores-Saavedra J, Asa SL, Baloch ZW, Sobrinho- Simoes M, Wenig B: Papillary carcinoma. In DeLellis R A, Lloyd RV, Heitz PU, Eng C. (Eds): WHO classification of tumours. Pathology & Genetics Tumors of Endocrine Organs. Lyon, IARC 2004, 57-66
4) El Demellawy D, Nasr A, Alowami S: Application of CD56 P63 and CK19 immunnohistochemistry in the diagnosis of papillary carcinoma of thyroid. Diagnostic Pathology 2008, 3:5.
5) Casey MB, Lohse CM, Lloyd RV: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3 and HBME-1. Endocr Pathol 2003, 14: 55-60
6) Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM Baloch ZW: Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002, 6: 710-713
7) Soda G, Antonaci A, Bosco D, Nardoni S, Melis M: Expression of bcl-2, c-erbB-2, p53 and p21 (waf1-cip1) protein in thyroid carcinomas. J Exp Clin Cancer Res 1999, 3: 363- 367
8) Zeromski J, Lawniczak M, Galbas K, Jenek R, Golusiński P: Expression of CD56/ N-CAM antigen and some other adhesion molecules in various human endocrine glands. Folia Histochem Cytobiol 1998, 36:119-125
9) Cavallaro U, Niedermeyer J, Fuxa M, Christofori G: N-CAM modulates tumour-cell adhesion to matrix by inducing FGFreceptor signaling. Nat Cell Biol 2001, 3: 650-657
10) Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL: Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001, 14: 338-342
11) Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E Bartolazzi A, Orlandi F, Papotti M: Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch 2004, 445: 183-188
12) Ordonez NG: Application of mesothelin immunstaining in tumor diagnosis. Am J Surg Pathol 2003, 27: 1418-1428
13) Kurita T, Medina RT, Mills AA, Cunha GR: Role of p63 and basal cells in prostate. Development 2004, 131: 4955-4964
14) Moll UM, Slade N: p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004, 2: 371-386
15) Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P Vancheri C, Vigneri P, Aloisi A, Vigneri R, Frasca F: The p53- homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer 2005, 12: 953-971
16) Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat C Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C: p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002, 8: 494-501
17) Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L Yang A, Montironi R, McKeon F, Loda M: p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000, 157: 1769-1775
18) Mase T, Funahashi H, Koshikawa T, Imai T, Nara Y, Tanaka Y Nakao A: HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 2003, 50: 173-177
19) Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G: The p53/p63/ p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000, 113: 1661-1670
20) Reis-Filho JS, Schmitt FC: Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 2002, 9: 280-289
21) Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME: Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004, 28: 1336-1340
22) Hirokawa M, Carney JA, Goellner JR, DeLellis RA, Heffess CS, Katoh R, Tsujimoto M, Kakudo K: Observer variation in encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 2002, 26: 1508-1514
23) Migita K, Eguchi K, Kawakami A, Ida H, Fukuda T, Kurata A, Ishikawa N, Ito K, Nagataki S: Detection of Leu-19 (CD56) antigen on human thyroid epithelial cells by an immunohistochemical method. Immunology 1991, 72: 246-249
24) Zeromski J, Biczysko M, Stajgis P, Lawniczak M, Biczysko W: CD56 (NCAM) antigen in glandular epithelium of human thyroid: light microscopic and ultrastructural study. Folia Histochem Cytobiol 1999; 37: 11-17
25) Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, Ruco L: Papillary carcinoma of the thyroid: low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 2007, 212 :411-419
26) Scognamiglio T, Hyjek E, Kao J, Chen YT: Diagnostic usefulness of HBME1, galectin-3, CK19 and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 2006, 126: 700-708
27) de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV Metze K, Ward LS: Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunstaining in the diagnosis of thyroid malignancy. Histopathology 2005, 47: 391-401
28) Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE: Expression of p63 in papillary thyroid carcinoma and in Hashimoto’s thyroiditis: a pathobiologic link? Hum Pathol 2003 34:764-769
){kind=link}
){kind=link}
){kind=link}